Global Clinical Site Accreditation Launches
Global Clinical Site Accreditation (GCSA) has launched with a commitment aimed at increasing clinical research and trial capacity and quality in the UK, as well as globally. GCSA awards a certification mark through an evidence-based approach.
“As a global clinical research organization, Parexel is focused on working with sites as a partner in the clinical development process,” said Agnieszka Gackowska, Senior Director, Global Site Solutions. “To this end, the ability to pivot in pandemic situations and conduct trials in potentially unpredictable situations—implementing new approaches like decentralized clinical trials—is key...as we work together to bring new therapies to patients in need.”
GCSA is an assessment, improvement, and accreditation organization. A collaboration between Future Shaping Holdings Ltd, the parent company of IAOCR, and Develop Consulting.
For more information, click here.
Semaglutide Significantly Improves Steatohepatitis, Fibrosis in Phase III MASH Trial
May 2nd 2025Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly semaglutide improved liver histology, metabolic markers, and weight loss in patients with biopsy-confirmed metabolic dysfunction–associated steatohepatitis and stage 2 or 3 fibrosis.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
